RE:RE:RE:RE:ONCY pelareorep + CD3 bispecific antibody true-killer comboRepost (2): another reason for Big Pharma's eagerness in ONCY's pelareorep ... a true tumor-killer combo that would not be effective without each other. Both bispecific T-cell engagers and oncolytic viruses are promising cancer therapies, but the new research demonstrates that combining the two approaches could work even better. The researchers first administered oncolytic reovirus to both syngeneic murine and humanized tumor models, then injected the CD3ε-bispecific antibodies. The combined treatment induced strong tumor regression and prolonged survival compared to each treatment option individually.
Preconditioning the tumor microenvironment with oncolytic reovirus resulted in the activation of immunologically cold tumors, explained the researchers. This in turn led to more successful engagement of bispecific antibodies, causing tumor cell death.
https://absoluteantibody.com/general/using-bispecific-antibody-reagents-to-further-research/
Noteable - (10/14/2022 7:54:46 PM)
Currently Roche's CD3 bispecific for lymphoma drug Lunsumio (monsunetuzumab) is an off-the-shelf antibody that has been given conditional approval in Europe and will be a contender with CAR-T therapy in liquid cancers. Lunsumio can be used alone or in combination with its checkpoint inhibitor atezolizumab.
Pfizer's bispecific elranatamab is an investigational B-cell maturation antigen (BCMA) CD3-targeted bispecific antibody in development for the treatment of multiple myeloma (MM).
Abbvie is another Big Pharma company involved in the development of CD3 bispecifics.
A bispecific antibody approach may allow for binding to targets on malignant cells, while simultaneously binding to CD3 on T cells, inducing activation and cytotoxic activity of T cells enabling lysis of target-expressing malignant cells.
ONCY's oncolytic virus facilitates CD3 binding while it "primes" the immune system for both an innate and adaptive immune response to the tumor cells and models the tumor microenvironment (TME) towards T-cell activation and the minimization of T-cell exhaustion.